We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
35 hedge funds and large institutions have $15.8M invested in Crescent Biopharma in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 13 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
0.02% less ownership
Funds ownership: 0.52% → 0.51% (-0.02%)
19% less funds holding
Funds holding: 43 → 35 (-8)
50% less capital invested
Capital invested by funds: $31.7M → $15.8M (-$15.9M)
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Holders
35
Holders Change
-8
Holders Change %
-18.6%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
13
Closed
10
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
-$92K
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$70.9K |
| 2 |
Charles Schwab
San Francisco,
California
|
+$44.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.5K |
| 4 |
Millennium Management
New York
|
+$22.6K |
| 5 |
Jane Street
New York
|
+$14.2K |
